The HIV latency reversing agent HODHBt inhibits the phosphatases PTPN1 and PTPN2
Nonreceptor tyrosine phosphatases (NTPs) play an important role in regulating protein phosphorylation and have been proposed as attractive therapeutic targets for cancer and metabolic diseases. We have previously identified that 3-Hydroxy-1,2,3-benzotriazin-4(3H)-one (HODHBt) enhanced STAT activatio...
| Published in: | JCI Insight |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
American Society for Clinical investigation
2024-09-01
|
| Subjects: | |
| Online Access: | https://doi.org/10.1172/jci.insight.179680 |
